The present application discloses compounds having the following formula:
or pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
, R
4
and R
5
are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.